The shares were picked up by two domestic fund houses. Kotak Mahindra Mutual Fund acquired 21.02 lakh shares, while Aditya Birla Sun Life Mutual Fund purchased 13.48 lakh shares. Both transactions were executed at the same price of Rs 2,968 per share.
Ajanta Pharma is a specialty pharmaceutical company with a presence across branded generics, emerging markets and select developed markets. The company has built a strong franchise in therapeutic segments such as ophthalmology, cardiology, dermatology and pain management, while also expanding its footprint in international markets.
The company has been one of the stronger performers in the pharmaceutical space, benefiting from steady earnings growth, healthy margins and a robust balance sheet. Investors have also favoured the stock due to its focus on branded formulations and relatively limited exposure to pricing pressures in the US generics market.
Ajanta Pharma reported good fourth quarter results, with revenue and EBITDA coming in 1-3%, ahead of analysts estimates. PAT was 23% higher than the views, helped by higher Other income and a lower tax rate. US generics business sustained robust growth momentum, up 47% YoY in USD terms
“We raise our FY27E-FY28E core earnings estimates by 2%. AJP trades at 31.2x FY27E core P/E. We retain our target price at Rs 3,115 based on 29.9x FY28E core P/E plus cash per share. We retain our Accumulate rating. Geopolitical disruptions to the business and a spike in raw materials price & freight cost are key risks to our call. We introduce FY29 estimates,” Elara Capital said post the earnings.
-1024x683.jpg "Florida Roads Become a Battleground for Illegal Immigration")
-1024x768.jpg "Red Snapper Used as Cudgel by Fed Judge")
